I-Chen Li1, Shan Lin1, Yueh-Ting Tsai2, Jui-Hsia Hsu1, Yen-Lien Chen1, Wen-Hsin Lin3, Chin-Chu Chen1,4,5,6. 1. Grape King Bio Ltd, Taoyuan City, Taiwan. 2. Testing Center, Super Laboratory Inc., New Taipei City, Taiwan. 3. School of Pharmacy, China Medical University, Taichung, Taiwan. 4. Institute of Food Science and Technology, National Taiwan University, Taipei City, Taiwan. 5. Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei City, Taiwan. 6. Institute of Biotechnology, National Changhua University of Education, Changhua, Taiwan.
Abstract
BACKGROUND: This is the first study to investigate the therapeutic effects of Cordyceps cicadae (C. cicadae) mycelia and its active compound N6 -(2-hydroxyethyl)adenosine (HEA) on blood glucose in genetically diabetic mice. RESULTS: Forty mice, 9 weeks of age, were divided into normal control, diabetic control, and three C. cicadae mycelia treated diabetic groups. After 9 weeks of continuous supplementation, the oral glucose tolerance test (OGTT) and homeostasis model of assessment-insulin resistance index showed significant glucose tolerance with C. cicadae mycelia. Furthermore, the effect of HEA is similar to that of C. cicadae mycelia in an OGTT, suggesting that HEA could be the major factor responsible for the functional properties of C. cicadae mycelia. CONCLUSION: Based on these findings, it is suggested that the therapeutic effect of C. cicadae mycelia may be driven by one of its active components, HEA, which could alleviate many diabetes complications in genetically obese mice and may offer promise as a supplement for diabetes management.
BACKGROUND: This is the first study to investigate the therapeutic effects of Cordyceps cicadae (C. cicadae) mycelia and its active compound N6 -(2-hydroxyethyl)adenosine (HEA) on blood glucose in genetically diabeticmice. RESULTS: Forty mice, 9 weeks of age, were divided into normal control, diabetic control, and three C. cicadae mycelia treated diabetic groups. After 9 weeks of continuous supplementation, the oral glucose tolerance test (OGTT) and homeostasis model of assessment-insulin resistance index showed significant glucose tolerance with C. cicadae mycelia. Furthermore, the effect of HEA is similar to that of C. cicadae mycelia in an OGTT, suggesting that HEA could be the major factor responsible for the functional properties of C. cicadae mycelia. CONCLUSION: Based on these findings, it is suggested that the therapeutic effect of C. cicadae mycelia may be driven by one of its active components, HEA, which could alleviate many diabetes complications in genetically obesemice and may offer promise as a supplement for diabetes management.